An NCI-designated Consortium Cancer Center
|
|
|
Weekly Research Newsletter
|
Week of December 12, 2022
|
|
|
Community Breast Cancer Awareness Event
Over the weekend of December 2-4, 2022, Moores Cancer Center (MCC), in coordination with Congregation Beth Am in San Diego North County and Sharsheret (a nationwide Jewish breast cancer organization that provides support for anyone facing breast cancer), held two panels to educate members of the San Diego community on the latest in breast cancer treatment, research, genetic risks (BRCA-1 and BRCA-2 mutations), and prevention.
|
|
|
|
A big thank you to Dr. Jennifer Matro, Dr. Jing Yang, and Dr. Julie Le, who all volunteered their time to participate on these important community education panels. Event participants also created 48 care packages (that included warm hats, fuzzy socks, playing cards, and activity books) for MCC breast cancer patients, which will be delivered to MCC next week to distribute to patients. Feedback received about not only event education, but also MCC physicians was extremely positive. Kudos to Dr. Matro, Dr. Yang, and Dr. Le for representing MCC!
|
|
|
Join the Work in Progress Seminar Series
Please join MCC's standing Work in Progress Seminar Series every first Wednesday of the month. If you are interested in presenting or joining, then please contact Program Coordinator, Diana Arroyo at d1arroyo@health.ucsd.edu.
|
|
|
Highlights from The Cancer Letter |
Joseph Califano Named Director of UC San Diego, Moores Cancer Center
Read full article on page 6 of The Cancer Letter, volume 48 number 42.
NYU Study Shows Cancer Cell Biology May Predict Response to Immunotherapy
Read full article on page 39 of The Cancer Letter, volume 48 number 42.
|
|
|
|
Pharmacology Seminar Series
Resolving Phospholipase Beta Regulation by G Proteins and the Membrane
Tuesday, December 13, 2022 at 12:00 p.m.
Leichtag Biomedical Research Building (Room 107)
Optional Zoom Link
Angeline M. Lyon, Ph.D.
Associate Professor of Chemistry and Biological Sciences Department of Chemistry
Purdue University, College of Science
Hosted by J. Silvio Gutkind, Ph.D.
|
|
|
|
Cancer Control Program, Work in Progress Seminar Series
Colorectal Cancer Disparities across Latin America: A Mortality Trend Analysis from 1990 to 2019
Wednesday, December 14, 2022 at 12:00 p.m.
Hybrid Meeting (In-Person/Virtual)
Moores Cancer Center, 2nd Floor
Comer Commons Conference Room
Zoom Link
Raphael Guimaraes, Ph.D.
Visiting Associate Researcher
Herbert Wertheim School of Public Health & Human Longevity Science
|
|
|
|
Solid Tumor Therapeutics Program
S1609 DART: Lessons Learned in Rare Tumor Immunotherapy
Wednesday, December 14, 2022, from 4:30 p.m. to 5:30 p.m.
Location Forthcoming
Sandip Patel, M.D.
Professor, Medical Oncology
Leader, Experimental Therapeutics
Director, Clinical Trials Office
UC San Diego
Deputy Director
San Diego Center for Precision Immunotherapy
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT
|
| |
2023 Cervical Cancer Awareness Summit
Thursday, January 19, 2023 from 10:00 a.m. to 12:00 p.m. PT
Join us virtually to learn from leaders in the field on the current and future state of cervical cancer treatment, research, and prevention.
|
|
|
CRTEC Beyond Academia: Exploring Careers in Science Policy
Tuesday, December 20, 2022 from 2:00 p.m. to 3:00 p.m.
|
|
|
Student Volunteers Available
Cancer Research, Training, and Education Coordination (CRTEC) has identified three motivated undergraduate students who are interested in volunteering in a lab at MCC. This is a win-win research experience for the students and your lab. Please contact Amy Spilkin, Ph.D. (aspilkin@health.ucsd.edu), if you would like to connect with one or more of these students:
|
- Third-year UCSD undergraduate majoring in Biology, minoring in Math
- Second-year UCSD premed undergraduate majoring in Human Biology
-
First-year UCSD undergraduate majoring in Cognitive and Behavioral Neuroscience
|
CRTEC administration will complete all necessary paperwork for these student volunteers.
|
|
|
Speed Mentoring Workshop, Faculty Sign Ups
Faculty Members of MCC are invited to serve a mentors at the MCC Speed Mentoring Workshops, organized by MCC CRTEC. These workshops serve not only undergraduate, graduate, and post-graduate students, but also project scientists, and research scientists, and junior faculty. Please select the session(s) for which are are available to mentor, and please select all that apply. You will be scheduled for only one of the dates that you choose—providing several dates merely helps to coordinate schedules. You will be contacted with a confirmation of the schedule.
CRTEC Speed Mentoring takes place on the second Thursday of each month from 12:00 p.m. to 1:00 p.m. on Zoom. Participating faculty members will receive 1 hour of mentorship credit, approved by MCC leadership.
|
|
|
HIGHLIGHTED FUNDING OPPORTUNITIES
|
|
|
Krupp Endowed Fund Request for Applications - Fiscal Year 2024 Funding
The primary aim of the Krupp Endowed Fund is to support research that examines the benefits of integrative medicine approaches that show the greatest promise of bettering human health for the largest number of people, at the lowest cost. The primary objective of the fund is to support innovative clinical research in the fields of diet/nutrition; medicinal food and herbs; homeopathy; and food derived macro- and micronutrients.
Letter of Intent (LOI) Deadline: Monday, December 12, 2022 by 11:59 p.m. PT
Full Application Deadline (by invitation only): Monday, February 27, 2023 by 11:59 p.m. PT
Notice of Awards: April 2023
Funding Cycle: Starts FY 2024 (July 1, 2023)
Click here for application details.
For questions regarding KEF funding or membership, please contact KruppREC@ucsd.edu
|
| |
Department of Defense (DoD) Breast Cancer Research Program (BCRP), Clinical Research Extension Award (CREA)
Three expected awards; estimated total program funding $26,400,000
The FY22 DoD BCRP CREA aims to extend the data collection, follow-up, and analysis of breast cancer clinical research studies. The goal of this award is to increase the clinically relevant effect of breast cancer patient participation in clinical research by addressing the knowledge lost due to limited or early termination of patient follow-up and sample collection and analysis. The award may not be used to support a clinical trial directly.
Deadline: December 13, 2022
|
|
|
Advancing Head and Neck Cancer Early Detection Research (AHEAD)
Maximum funding $500,000 direct costs/year for 5 years.
The purpose of this Funding Opportunity Announcement (FOA) is to accelerate translation of research to improve early detection of head and neck cancers (HNC). This FOA seeks applications that target early detection of HNC by (1) applying molecular, cellular, and multi-omics signatures to clinical studies for differentiating benign from premalignant lesions and (2) identifying prognostic signatures on the transformation from premalignant to malignant lesions.
Deadline: January 27, 2023 at 5:00 p.m.
|
Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
Application budgets may not exceed $500,000 in direct costs per year for the UG3 phase and may not exceed $750,000 in direct costs per year for the UH3 phase.
Through this FOA, the National Cancer Institute (NCI) intends to accelerate the development of evidence-based cancer-related interventions that reflect the diversity of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. This FOA will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.
Deadline: February 14, 2023 by 5:00 p.m. and June 14, 2023 by 5:00 p.m.
|
|
|
2023 ACTRI Pilot Projects – Community Research Partnership
These UCSD, Altman Clinical and Translational Research Institute (ACTRI) grants are (1) 1-year competitive awards (up to $30,000) to provide funding for early-stage projects and (2) available to all ACTRI members with faculty appointments; funding priority is given to early-career faculty.
Requests for assistance with identifying potential community or academic partners: October 2022 - November 2022
Deadline: Friday, February 24, 2023 by 2:00 p.m. PT
|
|
|
OTHER FUNDING OPPORTUNITIES
|
|
|
Alex's Lemonade Stand 2023 Young Investigator Grant
This grant offers up to $50,000 in direct costs per year for 3 years
Deadline: December 12, 2022 at 8:00 p.m. ET
|
|
|
Basic/Translational Research on Health Disparities Among Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed)
NCI intends to commit $3.5M in FY 2023 to fund 7-10 awards and $3.5M in FY 2024 to fund another 7-10 awards.
Deadline: December 15, 2022 at 5:00 p.m. PT
|
|
|
Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed)
The combined budget for direct costs for the 2-year project period may not exceed $275,000; no more than $200,000 may be requested in any single year; the maximum project period is 2 years.
Deadline: December 15, 2022 at 5:00 p.m. PT
|
| Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional)
Budgets are limited to $2 million in direct costs per year for partnerships of two institutions and $2.5 million in direct costs per year for partnerships of three institutions; maximum duration 5 years.
Deadline: January 6, 2023 at 5:00 p.m. PT; LOI due 30 days prior
|
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20 Clinical Trial Not Allowed)
The combined budget for ISUPS and CC cannot exceed $375,000 in direct costs per year; maximum duration 4 years.
Deadline: January 6, 2023 at 5:00 p.m. PT; LOI due 30 days prior
|
|
|
Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Liquid Biopsy Research Laboratories (U01 and U24)
U01 Award: $600,000 direct costs per year for 5 years
U24 Award: $450,000 direct costs per year for 5 years
Deadline: January 10, 2023 at 4:00 p.m. ET
|
| NCI Cancer Screening Research Network: Coordinating and Communication Center (UG1 Clinical Trial Required)
NCI intends to commit $1.5M in FY 2024 to fund 1 award; $2M is expected to be allocated per year in subsequent years for the CCC; maximum project period is 4 years.
LOI Deadline: January 28, 2023
Application Deadline: February 28, 2023
|
| NCI Cancer Screening Research Network: Statistics and Data Management Center (UG1 Clinical Trial Required)
NCI intends to commit $1M in FY 2024 to fund 1 award. $2M is expected to be allocated per year in subsequent years for the SDMC; maximum project period is 4 years.
LOI Deadline: January 28, 2023
Application Deadline: February 28, 2023
|
|
|
NCI Cancer Screening Research Network: ACCrual, Enrollment, and Screening Sites (ACCESS) Hub (UG1 Clinical Trial Required)
NCI intends to commit $8M in FY 2024 to fund 10-15 awards. $9M is expected to be allocated per year in subsequent years for ACCESS Hubs; requested budget must not exceed $750,000 in direct costs per year; maximum project period is 4 years.
LOI Deadline: January 28, 2023
Application Deadline: February 28, 2023
|
| Damon Runyon, Clinical Investigator Award
Award: $600,000 award for 3 years, distributed as $200,000 per year.
Deadline: February 1, 2023 at 4:00 p.m. ET
|
|
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
Maximum budget $375,000 direct costs/year for 5 years; NIH R01 standard due dates apply.
Deadline: February 5, 2023 at 5:00 p.m.
|
|
|
Coordinating Center for Cannabis and Cannabinoid Use Among Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U24 Clinical Trial Not Allowed)
Limited $500,000 direct costs per year; maximum project period is 5 years.
Deadline: February 17, 2023 at 5:00 p.m. PT
|
|
Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U01 Clinical Trial Not Allowed)
$500,000 direct costs per year; maximum project period is 5 years.
Deadline: February 18, 2023 at 5:00 p.m. PT
|
|
Notice of Special Interest (NOSI): Administrative Supplement for NCI Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)
One CAP-IT DRCC will be awarded with a maximum total cost of $800,000 per year (maximum direct cost is $480,000 per year) in fiscal year 2023; at least 1 full year on the parent grant must remain at the time of funding; application budget is limited to 4 years.
Deadline: February 28, 2023
|
|
|
POSTDOCTORAL FUNDING OPPORTUNITIES
|
|
|
Cancer Therapeutics Training (CT2) Program at Moores Cancer Center OPEN POSITIONS AVAILABLE
PIs: Dr. Michael Bouvet and Dr. Dwayne Stupack
Description: The goal of the Cancer Therapeutics Training (CT2) Program is to train the next generation of leaders in the field of cancer drug and diagnostics development. The CT2 Program is open to both M.D.s and Ph.D.s and provides an intensive 2-year period of research and training in the development of novel cancer therapeutics or diagnostics at the Moores Cancer Center. Trainees not only execute a research program under the direction of a member of the faculty of this Comprehensive Cancer Center, but also participate in coursework, seminars, and lectures. The research may be basic, translational, or clinical, yet all trainees will become versed in each major phase of the drug development process. Graduates of the program are prepared to transition to leadership roles in cancer therapeutics development in either an academic or commercial environment.
Salary/Stipend Information: NIH stipend scale
Application Procedure, Documents, and Requirements
|
-
Complete CT2 program application (form available to download from the website above)
- Curriculum vitae
- One-page personal statement
- Proof of U.S. citizenship or permanent resident status
- Three letters of recommendation (one from an identified mentor)
- Ph.D. or M.D. degree
|
For more information or to apply, please contact Amy Spilkin, Ph.D. at aspilkin@health.ucsd.edu
See WEBSITE for more details about CT2 program.
Deadline: January 15, 2023
|
| |
Saturday, January 28, 2023
|
|
|
Kyoto University Symposium
Tuesday, February 28, 2023 from 1:00 p.m. to 5:00 p.m.
Roth Auditorium
Sanford Consortium for Regenerative Medicine
|
|
|
|
Keynote Speaker
Dr. Shinya Yamanaka
Nobel Laureate in Physiology or Medicine 2012
Director Emeritus and Professor
Department of Life Science Frontiers
Center for iPS Cell Research and Application
Kyoto University
Read More
|
|
|
The symposium will be followed by a reception at the Bella Vista Cafe. Save the date and join us for this unique opportunity to reinvigorate academic collaborations with the prestigious university in Japan.
For more information, please contact Ms. Mariko Adachi, International Strategy Office, Kyoto University at osl.symposium@mail2.adm.kyoto-u.ac.jp
|
|
|
Big Data Training for Cancer Research - BigCare 2023 Summer Workshop
Friday, May 19, 2023 to Sunday, May 28, 2023
Purdue University
West Lafayette, Indiana
There is no cost for registration and tuition! The workshop will be held on-site at Purdue University, in West Lafayette, IN. There will be no cost for food or lodging, and travel scholarships will be available for a limited number of participants. Please visit the Purdue University Website for updates.
|
|
|
Newly Opened Clinical Trials
|
|
|
CE.7: A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HAWBRT) Plus Memantine for 515 Brain Metastases
PI: Hattangadi-Gluth, J
NCT: NCT03550391
|
| |
|
|
TAK-573-1001: An Open-Label, Dose-Escalation Phase 1 Study to Evaluate the Safety, Tolerability, pharmacokinetics, and Pharmacodynamics of TAK573 in Adult Patients with Metastatic Solid Tumors
PI: Daniels, G
NCT: NCT04157517
|
| | |
|
BAY 1841788 / 21516: Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer Using An External Control Arm (ARASEC)
PI: McKay, R
NCT: NCT04736199
|
| |
|
|
| Congratulations to Taylor Nonato for being recognized as CTO Staff of the Month for November, 2022!
The Clinical Trials Office and Genitourinary (GU) Team is recognizing Taylor for consistently going above and beyond as an all around team player while always maintaining a positive attitude. Taylor is reliable, enthusiastic, and has made a huge difference on the GU Team, despite the many obstacles the team has faced in the last few months. Taylor is incredibly hardworking and is someone the GU team can count on!
|
|
|
SHARED RESOURCE SPOTLIGHT
|
| |
|
The MCC Microscopy Shared Resource provides access to a wide array of equipment and services, which include not only regular epifluorescence, bright field, deconvolution, and confocal microscopy, but also specialized methods such as total internal reflection fluorescence (TIRF) and super resolution imaging. In addition, in vivo live animal imaging using the IVIS 200 imaging system permits non-invasive monitoring of cancer progression, gene expression patterns, cell trafficking, drug delivery, and treatment. Major equipment and capabilities include the following:
|
|
|
Nikon A1R Laser Scanning Confocal / TIRF / STORM System
|
- High-resolution and high-speed multidimensional confocal imaging, photo activation and bleaching, FRET, and FRAP
- Fast live-cell imaging in TIRF mode
- Super resolution (20 to 50 nm resolution) using stochastic optical reconstruction (STORM) and photo activation localization microscopy (PALM)
|
Keyence BZ-X700 Fluorescence Microscope
|
- Automated brightfield and fluorescence microscopy
-
Fast multi-channel X-Y stitching and Z acquisition
- Sensitivity ranging from the UV to the far red (800 nm)
|
IVIS 200 Whole Animal Imaging System
|
- Bioluminescence and fluorescence imaging in living animals (GFP, RFP, Cy5.5 ICG)
|
- Basic analysis tools such as segmentation, counting, and quantification; advanced Ai tools for automated denoising and image clarification
- 2D and 3D object measurement and tracking tools and deconvolution
|
|
|
-
Tamaki N, Ahlholm N, Luukkonen PK, Porthan K, Sharpton SR, Ajmera V, Kono Y (ZY), Dave S, Ahmed A, Sundaram V, Wilkinson MJ, Patton H, Gupta H, Cervantes V, Hernandez C, Lopez SJ, Loomba R, Baumgartner A, Richards L, Arkkila PE, Nemes K, Isoniemi H, Yki-Järvinen H, Loomba R (CCP). Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease. J Clin Invest. 2022 NOV 01; 132(21).
- Kwon Y, Mehta S, Clark M, Walters G, Zhong Y, Lee HN, Sunahara RK, Zhang J (CBS). Non-canonical β-adrenergic activation of ERK at endosomes. Nature. 2022 NOV 01; 611(7934):173-179.
-
Gupta S (CCP), Earles A, Bustamante R, Patterson OV, Gawron AJ, Kaltenbach TR, Yassin H, Lamm M, Shah SC (CCP), Saini SD, Fisher DA, Martinez ME (CCP), Messer K (CCP), Demb J, Liu L. Adenoma detection rate and clinical characteristics influence advanced neoplasia risk after colorectal polypectomy. Clin Gastroenterol Hepatol. 2022 OCT 18
-
Bootsma M, McKay RR (STT), Emamekhoo H, Bade RM, Schehr JL, Mannino MC, Singh A, Wolfe SK, Schultz ZD, Sperger J, Xie W, Signoretti S, Kyriakopoulos CE, Kosoff D, Abel EJ, Helzer KT, Rydzewski N, Bakhtiar H, Shi Y, Blitzer G, Bassetti M, Floberg J, Yu M, Sethakorn N, Sharifi M, et al. Longitudinal molecular profiling of circulating tumor cells in metastatic renal cell carcinoma. J Clin Oncol. 2022 NOV 01; 40(31):3633-3641.
|
|
|
To submit any announcements, funding opportunities, events, or other important items to the newsletter, please make use of the newsletter submission form that is linked below.
Please direct any questions that you may have to our Marketing and Communications Coordinator, Sarah Christie, at sjchristie@health.ucsd.edu
|
|
|
|
Want to be highlighted in the Moores Cancer Center newsletter or on the MCC website?
We want to know and share in all of our successes at MCC. To that end, we have created a pipeline for our members to share recent publications, awards, new appointments, and research highlights that you would like to see in our MCC weekly newsletter or on the website. Please provide us with the data we need to showcase your great work by completing the Member Survey linked below.
We sincerely thank you in advance for your time!
|
|
|
Moores Cancer Center (MCC) is not only one of only 52 National Cancer Institute (NCI)-designated comprehensive cancer centers in the nation, but also the only one providing multidisciplinary, research-driven detection, treatment, survivorship, and prevention of cancer in San Diego County. The 360 MCC member scientists and clinicians hail from 22 UC San Diego specialty departments, Rady Children’s Hospital, San Diego State University, and the La Jolla Institute of Immunology.
With strengths in stem cell research, immune-oncology, precision medicine, cancer disparities, and pre-cancer and risk research, MCC investigators address translational oncology and drug development through partnerships with biotechnology and pharmaceutical companies. Holding Comprehensive status since 2001, MCC was founded in 1977 by John Mendelsohn and received its NCI designation in 1978.
|
|
|
Department of Research Administration
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails. View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to sjchristie@ucsd.edu.
To continue receiving our emails, add us to your address book.
|
|
|
|